vimarsana.com

Page 4 - ஆயுட்காலம் வாழ்க்கை அறிவியல் தொடர்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo HSC Gene Therapy for Hereditary Angioedema

Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo HSC Gene Therapy for Hereditary Angioedema
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema

Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Pharming appoints Anurag Relan as Chief Medical Officer and Robert Friesen as Chief Scientific Officer

Pharming appoints Anurag Relan as Chief Medical Officer and Robert Friesen as Chief Scientific Officer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Pharming Group N V announces the reimbursement of RUCONEST® in Spain

Dit artikel delen Share this article LEIDEN, The Netherlands, June 4, 2021 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that an agreement has been reached with the Spanish Ministry of Health to grant reimbursement for RUCONEST® (conestat alfa) in Spain. RUCONEST® is the first and only plasma-free recombinant human C1 esterase inhibitor (rhC1INH) protein replacement therapy approved for the treatment of acute hereditary angioedema (HAE) attacks in adults and children aged 2 years and over. 1 HAE is a rare genetic condition characterized by recurrent, unpredictable episodic swellings of mucosal or cutaneous sites, causing pain, disfigurement, and disability, which last for hours and, occasionally, several days.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.